Statins and Cancer-Related Mortality: An Open Question

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 2, 2013, Pages 73-74

  Gazzerro, Patrizia ^a   Ciaglia, Elena ^a,b   Bifulco, Maurizio ^a,b  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FUNCTIONAL STATUS; HUMAN; LETTER; PATIENT COMPLIANCE; PLEIOTROPY; PRIORITY JOURNAL; RISK REDUCTION; SELF CARE; SOCIAL STATUS;

BIAS (EPIDEMIOLOGY); HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS;

EID: 84880256834     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12080     Document Type: Letter

References (12)

1. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012;64:102-46.
2. Cagney H. Statin use associated with reduced cancer-related mortality. Lancet Oncol 2012;13:e524.
3. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802.
4. Caporaso NE. Statins and cancer-related mortality. Let's work together. N Engl J Med 2012;367:1848-50.
5. Kraus MW, Keltner D. Signs of socioeconomic status: a thin-slicing approach. Psychol Sci 2009;20:99-106.
6. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Bøggild H, Olsen J et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005;60:534-42.
7. Brookhart A, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54.
8. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
9. Khemasuwan D, Chae YK, Gupta S, Carpio A, Yun JH, Neagu S et al. Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 2011;124:852-9.
10. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175, 000 people in 27 randomised trials of statin therapy. PLoS ONE 2012;7:e29849.
11. Broughton T, Sington J, Beales IL. Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study. BMC Gastroenterology 2012;12:36.
12. Soininen K, Niemi M, Kilkki E, Strandberg T, Kivist KT. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 2006;98:51-4.